Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTPN11 | Q06124 | 1/20 | 0.46 |
| ▸ | PTPRO | Q16827 | 1/20 | 0.46 |
| ▸ | LTB4R2 | Q9NPC1 | 6/20 | 0.40 |
| ▸ | NR1H4 | Q96RI1 | 6/20 | 0.39 |
| ▸ | NPC1 | O15118 | 1/20 | 0.38 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
| ▸ | RAB9A | P51151 | 1/20 | 0.38 |
| ▸ | STAT3 | P40763 | 6/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13711746 | 0.92 | LTB4R2 (0.46) | LTB4R2NR1H4STAT3 | |
| SCHEMBL1734796 | 0.90 | PTPN11 (0.55) | PTPN11PTPROLTB4R2STAT3 | |
| SCHEMBL12626834 | 0.87 | PTPN11 (0.53) | PTPN11PTPROLTB4R2NPC1HPGD | |
| SCHEMBL2859097 | 0.85 | PTPN11 (0.42) | PTPN11PTPROLTB4R2RAB9ASTAT3 | |
| SCHEMBL1812005 | 0.85 | PTPN11 (0.47) | PTPN11PTPROLTB4R2STAT3 | |
| SCHEMBL1812105 | 0.85 | PTPN11 (0.55) | PTPN11PTPROLTB4R2NPC1HPGD | |
| SCHEMBL1811147 | 0.84 | PTPN11 (0.56) | PTPN11PTPROLTB4R2STAT3 | |
| SCHEMBL1813364 | 0.84 | PTPN11 (0.51) | PTPN11PTPROLTB4R2NPC1HPGD | |
| SCHEMBL2859088 | 0.83 | PTPN11 (0.42) | PTPN11PTPROLTB4R2HPGDSTAT3 | |
| SCHEMBL1815735 | 0.82 | PTPN11 (0.67) | PTPN11PTPROSTAT3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1654247-B1 | ALKYNYL ARYL CARBOXAMIDES | MERCK SERONO SA (CH) | 2010-01-20 | — | — | EP | disclosed |
| US-7589232-B2 | Alkynyl aryl carboxamides | LABORATORIES SERONO S.A. (CH) | 2009-09-15 | — | — | US | disclosed |
| US-7589232-B2 | Alkynyl aryl carboxamides | LABORATORIES SERONO S.A. (CH) | 2009-09-15 | — | — | US | disclosed |
| US-20070105913-A1 | Alkynyl aryl carboxamides | APPLIED RESEARCH SYSTEMS ARS HOLDINGS N.V. (NL) | 2007-05-10 | — | — | US | disclosed |
| US-20070105913-A1 | Alkynyl aryl carboxamides | APPLIED RESEARCH SYSTEMS ARS HOLDINGS N.V. (NL) | 2007-05-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070105913-A1 | Alkynyl aryl carboxamides | ECHS1, IRS1, HCCS | PTPN11 97/4885PTPRO 51/4885LTB4R2 827/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.